CBLB and neoplasm: Interestingly, a marked enhancement of anti-tumor activity was seen when Cbl-b inhibitors and anti-PDL1 were used in combination in all models (Figure 7), thus highlighting the possibility that these classes of agents could be used for combinatorial immunotherapy.